Subscribe
  • Home
  • Issues
    • Online First
    • Issue Archive
    • Special Issues
  • Browse By Topic
    • Personalized Medicine
    • Economics & Value
    • FDA Approvals, News & Updates
    • COVID-19
    • Cholangiocarcinoma
    • View All Topics ›
  • Conference Correspondent
    • ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
    • ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
  • Web Exclusives
    • Web Exclusive Articles
    • Videos
    • Interview with the Innovators
    • Webinars
    • Quick Quiz
    • Press Releases
  • Association for Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Articles

Articles

Immuno-Oncology: The New Frontier?
ASCO 2014 – Immuno-Oncology, ASCO
Conference Correspondent
Read More

Ipilimumab Combined with Cytotoxic Chemotherapy in Metastatic Melanoma
ASCO 2014 – Immuno-Oncology, ASCO
Conference Correspondent
Read More

Doublets and Triple Combinations in Metastatic Melanoma
ASCO 2014 – Immuno-Oncology, ASCO
Conference Correspondent
Read More

Stereotactic Radiosurgery and Ipilimumab for Melanoma Brain Metastases
ASCO 2014 – Immuno-Oncology, ASCO
Conference Correspondent
Read More

Peginterferon alfa-2b Combined with Ipilimumab for Advanced Melanoma
ASCO 2014 – Immuno-Oncology, ASCO
Conference Correspondent
Read More

Single-Agent Nivolumab in Advanced NSCLC
ASCO 2014 – Immuno-Oncology, ASCO
Conference Correspondent
Read More

Nivolumab Combined with Platinum-Based Doublet Chemotherapy in Advanced NSCLC
ASCO 2014 – Immuno-Oncology, ASCO
Conference Correspondent
Read More

Next-Generation TKIs
ASCO 2014 – Lung Cancer, ASCO
Conference Correspondent
Read More

Value-Based Use of Molecular and Genomic Markers
ASCO 2014 – Lung Cancer, ASCO
Conference Correspondent
Read More

New Results with Existing Agents
ASCO 2014 – Lung Cancer, ASCO
Conference Correspondent
Read More

Page 230 of 330

  • 227
  • 228
  • 229
  • 230
  • 231
  • 232
  • 233

Top Trending Articles

1.
FDA Approves Acalabrutinib and Venetoclax Combination for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
2.
FDA Launches Unified Adverse Event Monitoring System to Enhance Transparency and Efficiency
3.
Financial Toxicity in Cancer Care: Why the Conversation Must Start Before Treatment Begins
Jan Hailey, MHL, CMC, CMCO, CMIS, CMOM, CMCA-E/M
  • Home
  • Issues
    • Online First
    • Issue Archive
    • Special Issues
  • Browse By Topic
    • Personalized Medicine
    • Economics & Value
    • FDA Approvals, News & Updates
    • COVID-19
    • Cholangiocarcinoma
    • View All Topics ›
  • Conference Correspondent
    • ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
    • ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
  • Web Exclusives
    • Web Exclusive Articles
    • Videos
    • Interview with the Innovators
    • Webinars
    • Quick Quiz
    • Press Releases
  • Association for Value-Based Cancer Care
  • Value-Based Care in Myeloma
Subscribe

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
  • About
  • About VBCC
  • Mission Statement
  • Advertising
  • Contact
  • Contribute
  • Submit a Manuscript
  • Editorial / Publishing Policies
  • Author Guidelines
  • Publications
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Cholangiocarcinoma News
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.